| personality traits |
phenotype |
37 |
20 |
FFM measure of personality traits, Five-Factor Model, major personality dimensions, personality, personality traits, psychological traits of interest |
| personalized medicine |
phenotype |
2 |
2 |
personalized medicine |
| pertussis toxin |
drug |
2 |
1 |
|
| Peru |
cohort |
2 |
— |
|
| PET |
drug |
2 |
2 |
positron emission tomography |
| PFA |
drug |
7 |
1 |
paraformaldehyde |
| p-factor |
phenotype |
7 |
2 |
general factor of liability for clinically-severe levels of psychopathology, general psychopathology factor, higher order p-factor, higher-order p-factor, p |
| Pfam |
drug |
3 |
— |
|
| PGC |
cohort |
21 |
16 |
PGC disorder working groups, PGC samples, PGC2 report, PGC3 standards, Psychiatric Genomics Consortium, Psychiatric Genomics Consortium Phase 2 |
| PGC AD |
cohort |
2 |
2 |
PGC, PGC Alcohol Dependence, Psychiatric Genomics Consortium AD |
| PGC cohorts |
cohort |
3 |
3 |
core PGC cohorts |
| PGC dataset |
cohort |
2 |
1 |
Psychiatric Genomics Consortium dataset, core PGC dataset |
| PGC GWAS |
cohort |
2 |
— |
Psychiatric Genomics Consortium GWAS |
| PGC meta-analysis |
cohort |
2 |
2 |
PGC meta-analyses |
| PGE2 |
drug |
3 |
2 |
Prostaglandin E2, prostaglandin E2 |
| PGK1 |
gene |
3 |
1 |
|
| PGs |
drug |
8 |
4 |
polygenic risk score, polygenic score, polygenic scores, proteoglycans |
| pH |
drug |
4 |
3 |
acidity, post-mortem pH |
| phagocytosis |
phenotype |
2 |
1 |
|
| pharmacological treatment |
drug |
4 |
3 |
|
